As of close of business last night, TRACON Pharmaceuticals Inc’s stock clocked out at $0.43, down -6.52% from its previous closing price of $0.46. In other words, the price has decreased by -$0.0300 from its previous closing price. On the day, 3349117 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of TCON’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.32. For the most recent quarter (mrq), Quick Ratio is recorded 0.89 and its Current Ratio is at 0.89.
On February 10, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $24.
H.C. Wainwright reiterated its Buy rating for the stock on December 23, 2019, while the target price for the stock was revised from $15 to $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 27 ’23 when THEUER CHARLES bought 47,000 shares for $0.75 per share. The transaction valued at 35,250 led to the insider holds 399,417 shares of the business.
THEUER CHARLES bought 3,999 shares of TCON for $2,639 on Apr 26 ’23. The President and CEO now owns 352,417 shares after completing the transaction at $0.66 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCON now has a Market Capitalization of 19.46M and an Enterprise Value of 11.14M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.63. Its current Enterprise Value per Revenue stands at 0.92 whereas that against EBITDA is 2.97.
Stock Price History:
Over the past 52 weeks, TCON has reached a high of $2.19, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.2433, while the 200-Day Moving Average is calculated to be 0.2414.
Shares Statistics:
It appears that TCON traded 2.90M shares on average per day over the past three months and 9.73M shares per day over the past ten days. A total of 44.27M shares are outstanding, with a floating share count of 40.26M. Insiders hold about 11.53% of the company’s shares, while institutions hold 11.23% stake in the company. Shares short for TCON as of Feb 29, 2024 were 448.68k with a Short Ratio of 0.15, compared to 1.22M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.00% and a Short% of Float of 1.01%.
Earnings Estimates
As of right now, 2 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.06, while EPS last year was -$0.36. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.2 and -$0.26 for the fiscal current year, implying an average EPS of -$0.23. EPS for the following year is -$0.07, with 2 analysts recommending between -$0.06 and -$0.08.
